News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
697,833 Results
Type
Article (39649)
Company Profile (247)
Press Release (657937)
Multimedia
Podcasts (48)
Webinars (12)
Section
Business (204142)
Career Advice (2007)
Deals (35415)
Drug Delivery (95)
Drug Development (81034)
Employer Resources (172)
FDA (16173)
Job Trends (14853)
News (345142)
Policy (32529)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (82)
Alliances (49419)
ALS (87)
Alzheimer's disease (1372)
Antibody-drug conjugate (ADC) (120)
Approvals (16174)
Artificial intelligence (245)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (104)
Biotechnology (175)
Bladder cancer (63)
Brain cancer (26)
Breast cancer (270)
Cancer (2140)
Cardiovascular disease (170)
Career advice (1675)
Career pathing (30)
CAR-T (145)
Cell therapy (406)
Cervical cancer (19)
Clinical research (65897)
Collaboration (814)
Compensation (518)
Complete response letters (19)
COVID-19 (2584)
CRISPR (37)
C-suite (230)
Cystic fibrosis (100)
Data (2088)
Decentralized trials (2)
Denatured (18)
Depression (41)
Diabetes (262)
Diagnostics (6354)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (119)
Drug pricing (97)
Drug shortages (25)
Duchenne muscular dystrophy (92)
Earnings (86411)
Editorial (35)
Employer branding (21)
Employer resources (146)
Events (112047)
Executive appointments (705)
FDA (17378)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (738)
Gene editing (100)
Generative AI (19)
Gene therapy (286)
GLP-1 (702)
Government (4410)
Grass and pollen (4)
Guidances (51)
Healthcare (18811)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (111)
Indications (28)
Infectious disease (2724)
Inflammatory bowel disease (133)
Inflation Reduction Act (8)
Influenza (50)
Intellectual property (92)
Interviews (311)
IPO (16500)
IRA (40)
Job creations (3629)
Job search strategy (1422)
Kidney cancer (10)
Labor market (38)
Layoffs (462)
Leadership (16)
Legal (7908)
Liver cancer (72)
Lung cancer (310)
Lymphoma (146)
Machine learning (5)
Management (58)
Manufacturing (294)
MASH (64)
Medical device (13355)
Medtech (13360)
Mergers & acquisitions (19442)
Metabolic disorders (667)
Multiple sclerosis (77)
NASH (16)
Neurodegenerative disease (83)
Neuropsychiatric disorders (27)
Neuroscience (1886)
NextGen: Class of 2025 (6512)
Non-profit (4477)
Northern California (2580)
Now hiring (39)
Obesity (358)
Opinion (204)
Ovarian cancer (73)
Pain (81)
Pancreatic cancer (81)
Parkinson's disease (146)
Partnered (21)
Patents (227)
Patient recruitment (104)
Peanut (46)
People (57245)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20519)
Phase II (29020)
Phase III (21627)
Pipeline (1132)
Policy (133)
Postmarket research (2563)
Preclinical (8684)
Press Release (64)
Prostate cancer (100)
Psychedelics (30)
Radiopharmaceuticals (245)
Rare diseases (373)
Real estate (5906)
Recruiting (65)
Regulatory (22224)
Reports (46)
Research institute (2319)
Resumes & cover letters (349)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (66)
Series A (127)
Series B (83)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2216)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3575)
State (2)
Stomach cancer (13)
Supply chain (67)
Tariffs (32)
The Weekly (28)
United States (22373)
Vaccines (672)
Venture capitalists (41)
Weight loss (231)
Women's health (35)
Worklife (15)
Date
Today (213)
Last 7 days (562)
Last 30 days (2504)
Last 365 days (32819)
2025 (9730)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37553)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (52)
Alaska (7)
Arizona (230)
Arkansas (13)
Asia (37794)
Australia (6179)
California (5896)
Canada (1964)
China (500)
Colorado (258)
Connecticut (265)
Delaware (138)
Europe (81093)
Florida (875)
Georgia (202)
Idaho (57)
Illinois (518)
India (25)
Indiana (305)
Iowa (10)
Japan (157)
Kansas (102)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (868)
Massachusetts (4402)
Michigan (216)
Minnesota (383)
Mississippi (2)
Missouri (80)
Montana (27)
Nebraska (25)
Nevada (60)
New Hampshire (62)
New Jersey (1676)
New Mexico (28)
New York (1684)
North Carolina (948)
North Dakota (7)
Northern California (2580)
Ohio (199)
Oklahoma (14)
Oregon (34)
Pennsylvania (1328)
Puerto Rico (11)
Rhode Island (32)
South America (1096)
South Carolina (21)
South Dakota (1)
Southern California (2216)
Tennessee (101)
Texas (879)
Utah (174)
Virginia (140)
Washington D.C. (61)
Washington State (541)
West Virginia (3)
Wisconsin (52)
697,833 Results for "neurosigma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NeuroSigma Announces Patent Application Protecting Use of Trigeminal Nerve Stimulation to Include Treatment of Dyslexia and Other Neurodevelopmental Disorders
January 22, 2025
·
2 min read
Biotech Beach
NeuroSigma Establishes Singapore Subsidiary
NeuroSigma, Inc. announced the launch of NeuroSigma Pte, Ltd., a Singapore corporation, representing NeuroSigma’s first foreign subsidiary.
July 12, 2023
·
3 min read
Policy
NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD
NeuroSigma announced that the U.S. Food and Drug Administration cleared use of NeuroSigma’s second-generation Monarch eTNS System for treating pediatric attention deficit hyperactivity disorder.
January 18, 2024
·
2 min read
Biotech Beach
NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore
NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA), the national body that regulates medical devices, therapeutics, and other healthcare products.
October 3, 2023
·
2 min read
Biotech Beach
NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System
NeuroSigma today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its second-generation Monarch eTNS System™ (Monarch 2.0).
November 7, 2023
·
1 min read
Business
NeuroSigma Announces Strategic Digital Marketing Partnership with Data360
NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating neurological and neuropsychiatric disorders, today announced the commencement of a strategic digital marketing partnership with Data360, a leading provider of targeted, online marketing for the healthcare industry.
January 31, 2023
·
3 min read
Biotech Beach
NeuroSigma Announces Commercial Launch of The Monarch eTNS® System for the Treatment of Pediatric ADHD at Annual Meeting of the American Academy of Child and Adolescent Psychiatry
NeuroSigma, Inc. today announced the commercial launch of The Monarch eTNS System at the annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Toronto.
October 17, 2022
·
2 min read
Biotech Beach
NeuroSigma Announces that Enrollment Commences in Two Large, Double-Blind Trials of eTNS for Pediatric ADHD
NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating neurological and neuropsychiatric disorders, today announced that enrollment has commenced in two large, multicenter double-blind trials of eTNS for pediatric attention-deficit/hyperactivity disorder (ADHD).
November 8, 2022
·
8 min read
Biotech Beach
NeuroSigma Announces Receipt of Permanent HCPCS Codes from CMS for Monarch eTNS System
NeuroSigma, Inc. announced that the Centers for Medicare & Medicaid Services has confirmed the durable medical equipment benefit category determination and two permanent Level II Healthcare Common Procedure Coding System codes for the Monarch eTNS® System, effective October 1, 2022, as part of the final coding decisions of its biannual update.
September 27, 2022
·
2 min read
Biotech Beach
NeuroSigma Announces a $5 Million Equity Investment by KT Corporation
NeuroSigma, Inc., a bioelectronic medical device company, announced that KT Corporation has made a $5 million equity investment in NeuroSigma.
December 8, 2021
·
4 min read
1 of 69,784
Next
